Manganese News and Research

RSS

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

Medical expert speaks about effects of sugar on human body

With the many forms of sugar available, from table sugar, to high-fructose corn syrup to agave and honey, understanding the differences between sugars and their effects on the body is not all sweet.

18 Feb 2011

Aging-associated protein deficiency may lead to positive breast cancer in women

The most common type of breast cancer in older women - estrogen and progesterone receptor positive breast cancer - has been linked to a protein that fends off aging-related cellular damage.

28 Jan 2011

New quantitative methods to detect small signs of tremor

Sensitive new quantitive methods could be used to detect small signs of increased tremor and impaired motor skills caused by exposure to certain metals, and to follow up the treatment of neurological disorders, reveals a thesis from the University of Gothenburg, Sweden.

4 Oct 2010

Manganese in water can harm children’s IQ: Study

A team of researchers led by Maryse Bouchard, adjunct professor at the Center for Interdisciplinary Research in Biology, Health, Environment and Society (CINBIOSE) of the Universit du Qu-bec Montr-al and a researcher at Sainte Justine University Hospital, and Donna Mergler, professor emerita in the Department of Biological Sciences and a member of CINBIOSE, recently completed a study showing that children exposed to high concentrations of manganese in drinking water performed worse on tests of intellectual functioning than children with lower exposures.

20 Sep 2010

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.

13 Aug 2010

Senate Commission presents 2010 list of MAK and BAT values containing new data on 61 substances

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.

29 Jul 2010

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and anti-aging.

17 Jun 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

Epidemiological study shows Parkinson's disease is more common among whites and Hispanics

The largest epidemiological study of Parkinson's disease in the United States has found that the disease is more common in the Midwest and the Northeast and is twice as likely to strike whites and Hispanics as blacks and Asians.

28 Jan 2010

Study finds no elevated risk of dust-related disease for subway workers

New York subway commuters may worry more about rats and rising fares than dust floating through the system, but for the workers who spend their whole shift below ground, air quality has long been a concern. Results from a new pilot study using miniaturized air samplers to look at steel dust exposure may help them breathe easier.

13 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months ended September 30, 2008.

28 Dec 2009

Medical report showing the devastating impacts of coal on human body released

Physicians for Social Responsibility today released a groundbreaking medical report, "Coal's Assault on Human Health," which takes a new look at the devastating impacts of coal on the human body.

23 Nov 2009

Study to test anti-tumor effects of AEOL 10150 initiated

Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts.

18 Nov 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

Advanced regeneration system for cleaning water wells

Wells are used to extract water from aquifers, natural underground stores of water found on layers of permeable rock, gravel or clay. The water is pumped up and transported via pipes to treatment works, where it is cleaned and filtered through gravel beds before being conveyed to domestic and business consumers via a network of smaller pipes or mains.

19 Oct 2009

Aeolus Pharmaceuticals raises $1.65 million from existing institutional shareholders

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the “Units”), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.

7 Oct 2009

No unsafe levels of air pollutants or metals detected at schools in Beaver and Erie counties: DEP

Air quality sampling by the state Department of Environmental Protection at schools in Beaver and Erie counties has not detected unsafe levels of air pollutants or metals, Environmental Protection Secretary John Hanger said today.

18 Sep 2009

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.

14 Sep 2009